{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:45:34Z","timestamp":1770831934369,"version":"3.50.1"},"reference-count":135,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northern New England Clinical and Translational Research Network","award":["HT94252410390"],"award-info":[{"award-number":["HT94252410390"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The transcription factor thyroid hormone receptor \u03b2 (TR\u03b2), a recognized tumor suppressor, interacts with chromatin-modifying protein complexes to modulate the transcriptome and induce a tumor suppression gene regulatory network. Recent studies have linked poorly differentiated and anaplastic thyroid cancers to aberrant epigenomic signaling, chromatin accessibility, and gene expression. As no enduring treatments are available for these aggressive thyroid cancers and treatment-resistant disease, unveiling the epigenomic coregulatory proteins mediating TR\u03b2 signaling will advance the understanding of the molecular mechanisms of TR\u03b2 action to block tumor progression and reveal potential novel therapeutic targets. In this review, we summarize novel findings on the epigenomic landscape in the context of TR\u03b2 in thyroid malignancy, including the identification of previously unrecognized TR\u03b2 interactors and the mapping of 9 distinct functional protein communities that constitute the TR\u03b2 interactome in thyroid cells. We also explore how targeting TR\u03b2 interactors using existing epigenetic enzyme inhibitors\u2014such as histone deacetylase, lysine-specific histone demethylase 1A, and bromodomain and extraterminal domain; inhibitors\u2014in combination with TR\u03b2 agonists, may work synergistically to reprogram tumor epigenetics and suppress oncogenic transcriptional programs.<\/jats:p>","DOI":"10.1210\/endocr\/bqaf116","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:32:36Z","timestamp":1752514356000},"source":"Crossref","is-referenced-by-count":3,"title":["Epigenomic Modulators and Thyroid Hormone Receptor \u03b2 Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer"],"prefix":"10.1210","volume":"166","author":[{"given":"John L","family":"Rustad","sequence":"first","affiliation":[{"name":"University of Vermont Cancer Center, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0005-4194","authenticated-orcid":false,"given":"Noelle E","family":"Gillis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lignos","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]},{"name":"Department of Pharmacology, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A","family":"Bright","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]},{"name":"Department of Biomedical Health Sciences, College of Nursing and Health Sciences, University of Vermont , Burlington, VT 05405 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3661","authenticated-orcid":false,"given":"Seth","family":"Frietze","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]},{"name":"Department of Biomedical Health Sciences, College of Nursing and Health Sciences, University of Vermont , Burlington, VT 05405 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-8788","authenticated-orcid":false,"given":"Frances E","family":"Carr","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]},{"name":"Department of Pharmacology, Larner College of Medicine, University of Vermont , Burlington, VT 05405 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"1-2","key":"2025072505321167900_bqaf116-B1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000486422","article-title":"Heterogeneity of thyroid cancer","volume":"85","author":"Chmielik","year":"2018","journal-title":"Pathobiology"},{"issue":"3","key":"2025072505321167900_bqaf116-B2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr Pathol"},{"issue":"13","key":"2025072505321167900_bqaf116-B3","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/cancers13133200","article-title":"Poorly differentiated and anaplastic thyroid cancer: insights into genomics, microenvironment and new drugs","volume":"13","author":"Prete","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2025072505321167900_bqaf116-B4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tem.2009.03.011","article-title":"Thyroid receptor: roles in cancer","volume":"20","author":"Aranda","year":"2009","journal-title":"Trends Endocrinol Metab"},{"issue":"17","key":"2025072505321167900_bqaf116-B5","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.3390\/cancers13174254","article-title":"Thyroid hormone receptor beta as tumor suppressor: untapped potential in treatment and diagnostics in solid tumors","volume":"13","author":"Davidson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2025072505321167900_bqaf116-B6","doi-asserted-by":"crossref","first-page":"bqae115","DOI":"10.1210\/endocr\/bqae115","article-title":"Thyroid hormone receptors as tumor suppressors in cancer","volume":"165","author":"Zhu","year":"2024","journal-title":"Endocrinology"},{"issue":"10","key":"2025072505321167900_bqaf116-B7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1541-7786.MCR-20-0282","article-title":"Thyroid hormone receptor beta induces a tumor suppressive program in anaplastic thyroid cancer","volume":"18","author":"Bolf","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"10","key":"2025072505321167900_bqaf116-B8","doi-asserted-by":"crossref","first-page":"bqad135","DOI":"10.1210\/endocr\/bqad135","article-title":"TR\u03b2 agonism induces tumor suppression and enhances drug efficacy in anaplastic thyroid cancer in female mice","volume":"164","author":"Gillis","year":"2023","journal-title":"Endocrinology"},{"issue":"12","key":"2025072505321167900_bqaf116-B9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1089\/thy.2017.0551","article-title":"Pathological interactions between mutant thyroid hormone receptors and corepressors and their modulation by a thyroid hormone analogue with therapeutic potential","volume":"28","author":"Harrus","year":"2018","journal-title":"Thyroid"},{"issue":"20","key":"2025072505321167900_bqaf116-B10","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.3390\/ijms20204986","article-title":"Molecular functions of thyroid hormone signaling in regulation of cancer progression and anti-apoptosis","volume":"20","author":"Liu","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025072505321167900_bqaf116-B11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"13","key":"2025072505321167900_bqaf116-B12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025072505321167900_bqaf116-B13","doi-asserted-by":"crossref","first-page":"113826","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep"},{"issue":"5","key":"2025072505321167900_bqaf116-B14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/PAT.0b013e3283486178","article-title":"BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis","volume":"43","author":"Gauchotte","year":"2011","journal-title":"Pathology"},{"key":"2025072505321167900_bqaf116-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fendo.2020.00102","article-title":"Update on fundamental mechanisms of thyroid cancer","volume":"11","author":"Prete","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025072505321167900_bqaf116-B16","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1002\/cjp2.356","article-title":"Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma","volume":"10","author":"Gu","year":"2024","journal-title":"J Pathol Clin Res"},{"issue":"6","key":"2025072505321167900_bqaf116-B17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.13942","article-title":"Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing","volume":"75","author":"Duan","year":"2019","journal-title":"Histopathology"},{"issue":"1","key":"2025072505321167900_bqaf116-B18","doi-asserted-by":"crossref","first-page":"19154","DOI":"10.1038\/s41598-023-46466-5","article-title":"Characterization of the genomic alterations in poorly differentiated thyroid cancer","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"2025072505321167900_bqaf116-B19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejso.2017.05.002","article-title":"Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management","volume":"44","author":"Xu","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2025072505321167900_bqaf116-B20","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2025072505321167900_bqaf116-B21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025072505321167900_bqaf116-B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2020.01.005","article-title":"Molecular therapeutics for anaplastic thyroid cancer","volume":"61","author":"Pozdeyev","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"2025072505321167900_bqaf116-B23","doi-asserted-by":"crossref","first-page":"100409","DOI":"10.1016\/j.xgen.2023.100409","article-title":"Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction","volume":"3","author":"Xu","year":"2023","journal-title":"Cell Genom"},{"issue":"1","key":"2025072505321167900_bqaf116-B24","doi-asserted-by":"crossref","first-page":"101656","DOI":"10.1016\/j.beem.2022.101656","article-title":"Genomic and epigenomic profile of thyroid cancer","volume":"37","author":"Acu\u00f1a-Ruiz","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2025072505321167900_bqaf116-B25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2017.05.022","article-title":"Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer","volume":"469","author":"Sasanakietkul","year":"2018","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2025072505321167900_bqaf116-B26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-021-09665-2","article-title":"Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know?","volume":"32","author":"Volante","year":"2021","journal-title":"Endocr Pathol"},{"issue":"3","key":"2025072505321167900_bqaf116-B27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3803\/EnM.2017.32.3.326","article-title":"Epigenetic modifications: novel therapeutic approach for thyroid cancer","volume":"32","author":"Zhu","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"2025072505321167900_bqaf116-B28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/ph16040559","article-title":"Epigenetic targets and their inhibitors in thyroid cancer treatment","volume":"16","author":"Zhang","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"2025072505321167900_bqaf116-B29","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/s41388-022-02242-9","article-title":"Regulation of cancer stem cell activity by thyroid hormone receptor \u03b2","volume":"41","author":"Doolittle","year":"2022","journal-title":"Oncogene"},{"issue":"6","key":"2025072505321167900_bqaf116-B30","doi-asserted-by":"crossref","first-page":"e220306","DOI":"10.1530\/ERC-22-0306","article-title":"Reactivated thyroid hormone receptor \u03b2 attenuates anaplastic thyroid cancer (ATC) stem cell activity","volume":"30","author":"Zhu","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025072505321167900_bqaf116-B31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1158\/0008-5472.CAN-08-2198","article-title":"Thyroid hormone receptor \u03b21 acts as a potent suppressor of tumor invasiveness and metastasis","volume":"69","author":"Mart\u00ednez-Iglesias","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"2025072505321167900_bqaf116-B32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/en.2012-1728","article-title":"Reactivation of the silenced thyroid hormone receptor \u03b2 gene expression delays thyroid tumor progression","volume":"154","author":"Kim","year":"2013","journal-title":"Endocrinology"},{"issue":"2","key":"2025072505321167900_bqaf116-B33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1089\/thy.2013.0054","article-title":"Inhibition of tumorigenesis by the thyroid hormone receptor \u03b2 in xenograft models","volume":"24","author":"Kim","year":"2014","journal-title":"Thyroid"},{"issue":"7","key":"2025072505321167900_bqaf116-B34","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.bbagen.2012.03.012","article-title":"Thyroid hormone receptors, cell growth and differentiation","volume":"1830","author":"Pascual","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2025072505321167900_bqaf116-B35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"issue":"2","key":"2025072505321167900_bqaf116-B36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/clinem\/dgae532","article-title":"The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma","volume":"110","author":"Wang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025072505321167900_bqaf116-B37","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/nar\/gkab1287","article-title":"Thyroid hormone dependent transcriptional programming by TR\u03b2 requires SWI\/SNF chromatin remodelers","volume":"50","author":"Gillis","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2025072505321167900_bqaf116-B38","first-page":"540","article-title":"The human thyrotropin-releasing hormone gene is regulated by thyroid hormone through two distinct classes of negative thyroid hormone response elements","volume":"9","author":"Hollenberg","year":"1995","journal-title":"Mol Endocrinol"},{"issue":"4","key":"2025072505321167900_bqaf116-B39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1172\/JCI19479","article-title":"Thyroid hormone action: a binding contract","volume":"112","author":"Lazar","year":"2003","journal-title":"J Clin Invest"},{"issue":"5","key":"2025072505321167900_bqaf116-B40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1210\/me.2002-0308","article-title":"Transcriptional activation by thyroid hormone receptor-beta involves chromatin remodeling, histone acetylation, and synergistic stimulation by p300 and steroid receptor coactivators","volume":"17","author":"Lee","year":"2003","journal-title":"Mol Endocrinol"},{"issue":"9","key":"2025072505321167900_bqaf116-B41","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1073\/pnas.93.9.4273","article-title":"Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53","volume":"93","author":"Yap","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2025072505321167900_bqaf116-B42","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1093\/emboj\/18.19.5389","article-title":"Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of the thyrotropin beta gene","volume":"18","author":"Sasaki","year":"1999","journal-title":"EMBO J"},{"issue":"1","key":"2025072505321167900_bqaf116-B43","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1038\/ncomms8048","article-title":"Transcriptional activation by the thyroid hormone receptor through ligand-dependent receptor recruitment and chromatin remodelling","volume":"6","author":"Gr\u00f8ntved","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"2025072505321167900_bqaf116-B44","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.bbagen.2012.07.001","article-title":"The in vivo role of nuclear receptor corepressors in thyroid hormone action","volume":"1830","author":"Astapova","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"5-6","key":"2025072505321167900_bqaf116-B45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1101\/gad.345686.120","article-title":"A coregulator shift, rather than the canonical switch, underlies thyroid hormone action in the liver","volume":"35","author":"Shabtai","year":"2021","journal-title":"Genes Dev"},{"issue":"6","key":"2025072505321167900_bqaf116-B46","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1210\/en.2018-00128","article-title":"Thyroid hormone receptor \u03b2 suppression of RUNX2 is mediated by brahma-related gene 1\u2013dependent chromatin remodeling","volume":"159","author":"Gillis","year":"2018","journal-title":"Endocrinology"},{"issue":"1","key":"2025072505321167900_bqaf116-B47","doi-asserted-by":"crossref","first-page":"19790","DOI":"10.1038\/s41598-024-70242-8","article-title":"Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-\u03b2 agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"14","author":"Suvarna","year":"2024","journal-title":"Sci Rep"},{"key":"2025072505321167900_bqaf116-B48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-beta (TR\u03b2) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"5088","key":"2025072505321167900_bqaf116-B49","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1126\/science.1360703","article-title":"Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors","volume":"258","author":"Yoshinaga","year":"1992","journal-title":"Science"},{"issue":"10","key":"2025072505321167900_bqaf116-B50","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/nar\/22.10.1815","article-title":"Two human homologues of Saccharomyces cerevisiae SWI2\/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor","volume":"22","author":"Chiba","year":"1994","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2025072505321167900_bqaf116-B51","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1002\/j.1460-2075.1993.tb06112.x","article-title":"A human homologue of Saccharomyces cerevisiae SNF2\/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor","volume":"12","author":"Muchardt","year":"1993","journal-title":"EMBO J"},{"issue":"2","key":"2025072505321167900_bqaf116-B52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/MCB.17.2.895","article-title":"Glucocorticoid receptor-glucocorticoid response element binding stimulates nucleosome disruption by the SWI\/SNF complex","volume":"17","author":"Ostlund Farrants","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2025072505321167900_bqaf116-B53","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/MCB.20.6.2004-2013.2000","article-title":"Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor \u03c41 activation domain","volume":"20","author":"Wallberg","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"17","key":"2025072505321167900_bqaf116-B54","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.1128\/MCB.23.17.6210-6220.2003","article-title":"BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation","volume":"23","author":"Hsiao","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2025072505321167900_bqaf116-B55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bpj.2015.06.044","article-title":"Structural modeling of GR interactions with the SWI\/SNF chromatin remodeling complex and C\/EBP","volume":"109","author":"Muratcioglu","year":"2015","journal-title":"Biophys J"},{"issue":"23","key":"2025072505321167900_bqaf116-B56","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.1128\/MCB.20.23.8879-8888.2000","article-title":"A specificity and targeting subunit of a human SWI\/SNF family-related chromatin-remodeling complex","volume":"20","author":"Nie","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2025072505321167900_bqaf116-B57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/MCB.01301-07","article-title":"The HSA domain of BRG1 mediates critical interactions required for glucocorticoid receptor-dependent transcriptional activation in vivo","volume":"28","author":"Trotter","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2025072505321167900_bqaf116-B58","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1210\/me.2007-0492","article-title":"Participation of brahma-related gene 1 (BRG1)-associated factor 57 and BRG1-containing chromatin remodeling complexes in thyroid hormone-dependent gene activation during vertebrate development","volume":"22","author":"Heimeier","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"51","key":"2025072505321167900_bqaf116-B59","doi-asserted-by":"crossref","first-page":"40463","DOI":"10.1074\/jbc.M007864200","article-title":"A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI\/SNF complex and the corepressor KAP-1*","volume":"275","author":"Underhill","year":"2000","journal-title":"J Biol Chem"},{"issue":"11","key":"2025072505321167900_bqaf116-B60","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/sj.emboj.7600231","article-title":"BRG1\/BRM and prohibitin are required for growth suppression by estrogen antagonists","volume":"23","author":"Wang","year":"2004","journal-title":"EMBO J"},{"issue":"5","key":"2025072505321167900_bqaf116-B61","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/1541-7786.MCR-20-0289","article-title":"The bromodomain inhibitor PFI-3 sensitizes cancer cells to DNA damage by targeting SWI\/SNF","volume":"19","author":"Lee","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"5","key":"2025072505321167900_bqaf116-B62","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/ph18050608","article-title":"Structural activity relationship analysis of new diphenyl PFI-3 analogues targeting for the treatment of glioblastoma","volume":"18","author":"Hwang","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"Suppl 1","key":"2025072505321167900_bqaf116-B63","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2023-178090","article-title":"Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1\/BRM (SMARCA4\/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies","volume":"142","author":"DiNardo","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2025072505321167900_bqaf116-B64","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025072505321167900_bqaf116-B65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"21","key":"2025072505321167900_bqaf116-B66","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41388-021-01781-x","article-title":"Exploiting vulnerabilities of SWI\/SNF chromatin remodelling complexes for cancer therapy","volume":"40","author":"Wanior","year":"2021","journal-title":"Oncogene"},{"issue":"16","key":"2025072505321167900_bqaf116-B67","doi-asserted-by":"crossref","first-page":"11177","DOI":"10.1021\/acs.jmedchem.2c00662","article-title":"GNE-064: a potent, selective, and orally bioavailable chemical probe for the bromodomains of SMARCA2 and SMARCA4 and the fifth bromodomain of PBRM1","volume":"65","author":"Taylor","year":"2022","journal-title":"J Med Chem"},{"issue":"6","key":"2025072505321167900_bqaf116-B68","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.3390\/ijms24065993","article-title":"GSK2801 reverses paclitaxel resistance in anaplastic thyroid cancer cell lines through MYCN downregulation","volume":"24","author":"Molteni","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025072505321167900_bqaf116-B69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2025072505321167900_bqaf116-B70","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.7150\/thno.66142","article-title":"KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt\/\u03b2-catenin signaling pathway","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"2025072505321167900_bqaf116-B71","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21873\/anticanres.13220","article-title":"Histone deacetylase inhibitors and anaplastic thyroid carcinoma","volume":"39","author":"Spartalis","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"2025072505321167900_bqaf116-B72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"2025072505321167900_bqaf116-B73","doi-asserted-by":"crossref","first-page":"43008","DOI":"10.18632\/oncotarget.17398","article-title":"Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2025072505321167900_bqaf116-B74","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"9","key":"2025072505321167900_bqaf116-B75","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/ERC-19-0107","article-title":"Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer","volume":"26","author":"Zhu","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2025072505321167900_bqaf116-B76","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbrc.2018.03.184","article-title":"AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo","volume":"499","author":"Xu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2025072505321167900_bqaf116-B77","doi-asserted-by":"crossref","first-page":"853652","DOI":"10.3389\/fcell.2022.853652","article-title":"AZD5153, a bivalent BRD4 inhibitor, suppresses hepatocarcinogenesis by altering BRD4 chromosomal landscape and modulating the transcriptome of HCC cells","volume":"10","author":"Lin","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2025072505321167900_bqaf116-B78","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-16-0141","article-title":"AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies","volume":"15","author":"Rhyasen","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2025072505321167900_bqaf116-B79","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025072505321167900_bqaf116-B80","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"issue":"48","key":"2025072505321167900_bqaf116-B81","doi-asserted-by":"crossref","first-page":"79637","DOI":"10.18632\/oncotarget.12876","article-title":"Therapeutic efficacy of the bromodomain inhibitor OTX015\/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes","volume":"7","author":"Boi","year":"2016","journal-title":"Oncotarget"},{"issue":"51","key":"2025072505321167900_bqaf116-B82","doi-asserted-by":"crossref","first-page":"84675","DOI":"10.18632\/oncotarget.13181","article-title":"OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations","volume":"7","author":"Riveiro","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"2025072505321167900_bqaf116-B83","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","article-title":"Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628","volume":"6","author":"Stathis","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2025072505321167900_bqaf116-B84","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.jmedchem.4c02535","article-title":"Discovery of FHD-286, a first-in-class, orally bioavailable, allosteric dual inhibitor of the brahma homologue (BRM) and brahma-related gene 1 (BRG1) ATPase activity for the treatment of SWItch\/sucrose non-fermentable (SWI\/SNF) dependent cancers","volume":"68","author":"Vaswani","year":"2025","journal-title":"J Med Chem"},{"issue":"4","key":"2025072505321167900_bqaf116-B85","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(92)90603-A","article-title":"The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene","volume":"71","author":"Gu","year":"1992","journal-title":"Cell"},{"issue":"5","key":"2025072505321167900_bqaf116-B86","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1097-2765(02)00740-2","article-title":"ALL-1 Is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation","volume":"10","author":"Nakamura","year":"2002","journal-title":"Mol Cell"},{"issue":"1","key":"2025072505321167900_bqaf116-B87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13072-018-0203-3","article-title":"KDM1A microenvironment, its oncogenic potential, and therapeutic significance","volume":"11","author":"Ismail","year":"2018","journal-title":"Epigenetics Chromatin"},{"issue":"3","key":"2025072505321167900_bqaf116-B88","first-page":"499","article-title":"Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma","volume":"54","author":"Kong","year":"2013","journal-title":"Rom J Morphol Embryol"},{"issue":"8","key":"2025072505321167900_bqaf116-B89","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1111\/jcmm.14311","article-title":"Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1\/MMP9 pathway in papillary thyroid cancer","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"7","key":"2025072505321167900_bqaf116-B90","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1210\/clinem\/dgaa182","article-title":"Lysine-specific demethylase 1 affects the progression of papillary thyroid carcinoma via HIF1\u03b1 and microRNA-146a","volume":"105","author":"Long","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025072505321167900_bqaf116-B91","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41388-018-0483-x","article-title":"GABPA inhibits invasion\/metastasis in papillary thyroid carcinoma by regulating DICER1 expression","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"issue":"27","key":"2025072505321167900_bqaf116-B92","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1021\/bi700664y","article-title":"Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine","volume":"46","author":"Yang","year":"2007","journal-title":"Biochemistry"},{"issue":"5","key":"2025072505321167900_bqaf116-B93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00487-3","article-title":"Superior efficacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells","volume":"11","author":"Fiskus","year":"2021","journal-title":"Blood Cancer J"},{"issue":"37","key":"2025072505321167900_bqaf116-B94","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1038\/sj.onc.1210611","article-title":"The human Mi-2\/NuRD complex and gene regulation","volume":"26","author":"Denslow","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"2025072505321167900_bqaf116-B95","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4161\/epi.4.8.10108","article-title":"The Mi-2\/NuRD complex: a critical epigenetic regulator of hematopoietic development, differentiation and cancer","volume":"4","author":"Ram\u00edrez","year":"2009","journal-title":"Epigenetics"},{"issue":"14","key":"2025072505321167900_bqaf116-B96","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.jmb.2016.04.025","article-title":"The nucleosome remodeling and deacetylase complex NuRD is built from preformed catalytically active sub-modules","volume":"428","author":"Zhang","year":"2016","journal-title":"J Mol Biol"},{"issue":"2","key":"2025072505321167900_bqaf116-B97","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0092-8674(03)00234-4","article-title":"MTA3, a Mi-2\/NuRD complex subunit, regulates an invasive growth pathway in breast cancer","volume":"113","author":"Fujita","year":"2003","journal-title":"Cell"},{"issue":"12","key":"2025072505321167900_bqaf116-B98","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1210\/me.2004-0258","article-title":"Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells","volume":"18","author":"Fujita","year":"2004","journal-title":"Mol Endocrinol"},{"issue":"5","key":"2025072505321167900_bqaf116-B99","doi-asserted-by":"crossref","first-page":"e62986","DOI":"10.1371\/journal.pone.0062986","article-title":"The metastasis-associated gene MTA3, a component of the Mi-2\/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma","volume":"8","author":"Dong","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"2025072505321167900_bqaf116-B100","doi-asserted-by":"crossref","first-page":"eaav9810","DOI":"10.1126\/sciadv.aav9810","article-title":"Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2","volume":"5","author":"Kim","year":"2019","journal-title":"Sci Adv"},{"key":"2025072505321167900_bqaf116-B101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.gdata.2015.12.029","article-title":"High-quality ChIP-seq analysis of MBD3 in human breast cancer cells","volume":"7","author":"Shimbo","year":"2016","journal-title":"Genom Data"},{"issue":"43","key":"2025072505321167900_bqaf116-B102","doi-asserted-by":"crossref","first-page":"42560","DOI":"10.1074\/jbc.M302955200","article-title":"The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity*","volume":"278","author":"Yao","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"2025072505321167900_bqaf116-B103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cancers7010030","article-title":"P53 acetylation: regulation and consequences","volume":"7","author":"Reed","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"6810","key":"2025072505321167900_bqaf116-B104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"issue":"1","key":"2025072505321167900_bqaf116-B105","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41467-023-36755-y","article-title":"Loss of p53 activates thyroid hormone via type 2 deiodinase and enhances DNA damage","volume":"14","author":"Nappi","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"2025072505321167900_bqaf116-B106","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/j.1349-7006.1992.tb02761.x","article-title":"P53 gene mutations associated with anaplastic transformation of human thyroid carcinomas","volume":"83","author":"Nakamura","year":"1992","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"2025072505321167900_bqaf116-B107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI116168","article-title":"High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas","volume":"91","author":"Fagin","year":"1993","journal-title":"J Clin Invest"},{"issue":"5","key":"2025072505321167900_bqaf116-B108","first-page":"1369","article-title":"Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland","volume":"52","author":"Ito","year":"1992","journal-title":"Cancer Res"},{"issue":"1","key":"2025072505321167900_bqaf116-B109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00019606-199403010-00003","article-title":"Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas","volume":"3","author":"Dobashi","year":"1994","journal-title":"Diagn Mol Pathol"},{"issue":"4","key":"2025072505321167900_bqaf116-B110","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1172\/JCI116385","article-title":"Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland","volume":"91","author":"Donghi","year":"1993","journal-title":"J Clin Invest"},{"issue":"11","key":"2025072505321167900_bqaf116-B111","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.21073","article-title":"Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations","volume":"103","author":"Quiros","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"2025072505321167900_bqaf116-B112","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0002-9440(10)64577-4","article-title":"Loss of p53 promotes anaplasia and local invasion in ret\/PTC1-induced thyroid carcinomas","volume":"157","author":"La Perle","year":"2000","journal-title":"Am J Pathol"},{"issue":"11","key":"2025072505321167900_bqaf116-B113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"1","key":"2025072505321167900_bqaf116-B114","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13277-013-1007-5","article-title":"Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions","volume":"35","author":"Giaginis","year":"2014","journal-title":"Tumor Biol"},{"issue":"4","key":"2025072505321167900_bqaf116-B115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2011.06.182","article-title":"Levels of histone acetylation in thyroid tumors","volume":"411","author":"Puppin","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"2025072505321167900_bqaf116-B116","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/labinvest.2009.50","article-title":"Epigenetic silencing of TTF-1\/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas","volume":"89","author":"Kondo","year":"2009","journal-title":"Lab Invest"},{"issue":"4","key":"2025072505321167900_bqaf116-B117","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1080\/21655979.2022.2068921","article-title":"GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"2025072505321167900_bqaf116-B118","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2025072505321167900_bqaf116-B119","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"issue":"14","key":"2025072505321167900_bqaf116-B120","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/cancers13143606","article-title":"Functional roles of bromodomain proteins in cancer","volume":"13","author":"Boyson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2025072505321167900_bqaf116-B121","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1093\/nar\/gkx802","article-title":"RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN","volume":"45","author":"Sancisi","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025072505321167900_bqaf116-B122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12672-019-00373-2","article-title":"The thyroid hormone receptor-RUNX2 axis: a novel tumor suppressive pathway in breast cancer","volume":"11","author":"Bolf","year":"2019","journal-title":"Horm Cancer"},{"issue":"8","key":"2025072505321167900_bqaf116-B123","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/en.2015-2046","article-title":"Thyroid hormone receptor-\u03b2 (TR\u03b2) mediates runt-related transcription factor 2 (Runx2) expression in thyroid cancer cells: a novel signaling pathway in thyroid cancer","volume":"157","author":"Carr","year":"2016","journal-title":"Endocrinology"},{"issue":"7327","key":"2025072505321167900_bqaf116-B124","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"3","key":"2025072505321167900_bqaf116-B125","first-page":"1021","article-title":"General mechanism of JQ1 in inhibiting various types of cancer","volume":"21","author":"Jiang","year":"2020","journal-title":"Mol Med Rep"},{"issue":"2","key":"2025072505321167900_bqaf116-B126","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/1078-0432.CCR-16-0914","article-title":"Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model","volume":"23","author":"Zhu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025072505321167900_bqaf116-B127","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2015.12.008","article-title":"Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer","volume":"469","author":"Gao","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2025072505321167900_bqaf116-B128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/ERC-15-0322","article-title":"MCM5 as a target of BET inhibitors in thyroid cancer cells","volume":"23","author":"Mio","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2025072505321167900_bqaf116-B129","first-page":"161","article-title":"Bromodomain-containing protein 4 is critical for the antiproliferative and pro-apoptotic effects of gambogic acid in anaplastic thyroid cancer","volume":"42","author":"Wang","year":"2018","journal-title":"Int J Mol Med"},{"issue":"20","key":"2025072505321167900_bqaf116-B130","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A Phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025072505321167900_bqaf116-B131","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41417-021-00375-9","article-title":"Combination of ZEN-3694 with CDK4\/6 inhibitors reverses acquired resistance to CDK4\/6 inhibitors in ER-positive breast cancer","volume":"29","author":"Kharenko","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"2025072505321167900_bqaf116-B132","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"issue":"7586","key":"2025072505321167900_bqaf116-B133","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"issue":"3","key":"2025072505321167900_bqaf116-B134","first-page":"3059","article-title":"Long non-coding RNA UCA1 promotes papillary thyroid cancer cell proliferation via miR-204-mediated BRD4 activation","volume":"18","author":"Li","year":"2018","journal-title":"Mol Med Rep"},{"issue":"9","key":"2025072505321167900_bqaf116-B135","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br J Cancer"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqaf116\/63753461\/bqaf116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/166\/9\/bqaf116\/63753461\/bqaf116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/166\/9\/bqaf116\/63753461\/bqaf116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:32:38Z","timestamp":1753435958000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqaf116\/8200872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":135,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqaf116","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,8]]},"article-number":"bqaf116"}}